Press release
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
– Late-Breaking Data from the Phase 3 ASCENT-04/KEYNOTE-D19 Study Evaluating Trodelvy® plus Keytruda® in First-Line PD-L1+ Metastatic Triple-Negative Breast
About this update from Gilead Sciences, Inc.
[{"type":"text","content":"\n– Late-Breaking Data from the Phase 3 ASCENT-04/KEYNOTE-D19 Study Evaluating Trodelvy® plus Keytruda® in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer –\n\n FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GILD) will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting May 30 – June 3 and the 2025 European Hematology Association (EHA) Annual Congress June 12 – 15. The studies span breast cancer and other solid tumors (glioblastoma, endometrial cancer, lung cancer, gastric cancer), as well as multiple blood cancers (multiple myeloma, large B-cell lymphoma, indolent non-Hodgkin lymphoma, acute lymphoblastic leukemia).\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514329114/en/\nAt ASCO, Gilead will present detailed late-breaking results from the Phase 3 ASCENT-04 study showing a statistically significant and clinically meaningful benefit in progression-free survival for Trodelvy® plus Keytruda® versus Keytruda and standard of care chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (Abstract #LBA109). Additionally, Kite research collaborators at the University of Pennsylvania Perelman School of Medicine will present Phase 1 results evaluating a novel investigational CAR T-cell therapy using a dual-target approach in patients with recurrent glioblastoma during an oral session at ASCO (Abstract #102).\n\nAt EHA, Kite and its partner Arcellx will present updated findings from the Phase 2 registrational iMMagine-1 study of anitocabtagene-autoleucel (anito-cel) in relapsed/refractory multiple myeloma during an oral presentation (Abstract #S201).\n\nAdditional abstracts supporting pipeline therapies (e.g., KITE-363, a C19/20 dual-target CAR T) and results from collaborative studies will also be presented as orals across ASCO and EHA.\n\n“Our oncology portfolio is broad and diverse by design, as we continue to innovate with next-generation therapies and combinations to deliver improved outcomes and ultimately seek to transform how cancer is treated,” said Dietmar Berger, MD, PhD, Chief Medical Officer, Gilead Sciences. “Data at ASCO and ...